Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESONANCE-Ⅲ: Nivolumab + SOX vs Nivolumab in Gastric Cancer
NCT04782791Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of nivolumab in gastric adenocarcinoma, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04782791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04782791.